Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SBP-101 with Gemcitabine and Nab-Paclitaxel in Metastatic Pancreatic Cancer
NCT03412799Phase 1Completed
- Sponsor
- Panbela Therapeutics
- Start
- Jun 2018
- Primary completion
- Feb 2022
- Modality
- Small Molecules
- Countries
- 2
01
Overview
Phase 1, open-label, single-arm trial of ivospemin in pancreatic ductal adenocarcinoma (PDAC), sponsored by Panbela Therapeutics. Primary endpoint: Recommended Phase 2 Dose of SBP-101 up to 12 months. Started Jun 2018; status: completed.
02
Drugs
ivospemin
03
Conditions
pancreatic ductal adenocarcinoma (PDAC)
Beyond the preview
Go deeper on NCT03412799.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03412799.